Market Overview:
The global endocrine peptides test market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of endocrine disorders, rising awareness about early diagnosis and treatment of these disorders, and technological advancements in the field of endocrinology. The estradiol segment is expected to account for the largest share of the global market in 2018 owing to its high prevalence among women across all age groups. By application, hospitals are expected to account for the largest share of the global market in 2018 followed by physicians’ offices, commercial laboratories, health care centers, and others.
Product Definition:
Endocrine peptides are hormones that are produced by the endocrine system. This test is used to measure the level of these hormones in the blood. The test can help to identify conditions such as diabetes, thyroid disorders, and tumors.
Estradiol (E2):
Estradiol (E2) is a type of estrogen. It's the most potent form of the female hormone and is produced by all women in small amounts. Estradiol levels peak during pregnancy and decline after menopause, usually reaching menopausal levels (the point at which a woman may experience hot flashes if she has not undergone hysterectomy) around 50 years of age.
Dehydroepiandrosterone Sulfate (DHEAS):
It is produced in the kidney, gastrointestinal tract, and adrenal glands in response to hypoglycemia and stress. DHEA supplements are available over-the-counter as dietary supplements or as prescription drugs used for the treatment of Cushing's syndrome, osteoarthritis, depression, chronic fatigue syndrome and other conditions related to deficiency of this peptide hormone.
Application Insights:
The others segment dominated the global endocrine peptides test market in terms of revenue share in 2017. This is due to a high prevalence of disorders related to the pituitary, thyroid, and sex glands. Moreover, this segment is expected to grow at a lucrative rate during the forecast period owing to increasing research activities for new applications of these hormones.
Hospitals were the largest application segment accounting for over 50% share in 2017 on account of factors such as availability of advanced diagnostic techniques supported by large lab facilities along with experienced personnel skilled in hormone analysis.
Regional Analysis:
North America dominated the global endocrine peptides test market in 2017. The presence of well-established healthcare infrastructure, high prevalence of target diseases, and rising awareness about early diagnosis are some factors attributing to this region’s largest share. Moreover, increasing R&D activities for the development of novel diagnostic tools is also expected to drive growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to a large population base with increased susceptibility towards target diseases such as diabetes and obesity due to changing lifestyles along with an increase in age group (Table 1). In addition, economic development coupled with improvement in healthcare facilities will further boost regional demand during the estimated time span.
Growth Factors:
- Increasing incidence of diabetes and other endocrine-related disorders
- Growing demand for peptide drugs as therapeutics for various diseases
- Rising awareness about the benefits of peptide therapy among healthcare professionals and patients
- Technological advancements in peptide synthesis and drug delivery systems
- Growing investments by pharmaceutical companies in R&D activities for developing novel peptide drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Endocrine Peptides Test Market Research Report
By Type
Estradiol (E2), Dehydroepiandrosterone Sulfate (DHEAS), Human Chorionic Gonadotropin (hCG), Progesterone, Luteinizing Hormone (LH), Thyroid Stimulating Hormone (TSH), Thyroid Prolactin, Others
By Application
Hospitals, Physicians’ offices, Commercial Laboratories, Health Care Centers
By Companies
Quest Diagnostics, Siemens Healthcare, Abbott Laboratories, bioMerieux
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
140
Number of Tables & Figures
98
Customization Available
Yes, the report can be customized as per your need.
Global Endocrine Peptides Test Market Report Segments:
The global Endocrine Peptides Test market is segmented on the basis of:
Types
Estradiol (E2), Dehydroepiandrosterone Sulfate (DHEAS), Human Chorionic Gonadotropin (hCG), Progesterone, Luteinizing Hormone (LH), Thyroid Stimulating Hormone (TSH), Thyroid Prolactin, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Physicians’ offices, Commercial Laboratories, Health Care Centers
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Quest Diagnostics
- Siemens Healthcare
- Abbott Laboratories
- bioMerieux
Highlights of The Endocrine Peptides Test Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Estradiol (E2)
- Dehydroepiandrosterone Sulfate (DHEAS)
- Human Chorionic Gonadotropin (hCG)
- Progesterone, Luteinizing Hormone (LH)
- Thyroid Stimulating Hormone (TSH)
- Thyroid Prolactin
- Others
- By Application:
- Hospitals
- Physicians’ offices
- Commercial Laboratories
- Health Care Centers
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Endocrine Peptides Test Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Endocrine peptides are small proteins that circulate in the blood and act as hormones. These peptides can influence a variety of physiological processes, including growth, development, metabolism, and reproduction. A test called an endocrine peptide assay is used to measure the levels of these proteins in the blood.
Some of the key players operating in the endocrine peptides test market are Quest Diagnostics, Siemens Healthcare, Abbott Laboratories, bioMerieux.
The endocrine peptides test market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Endocrine Peptides Test Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Endocrine Peptides Test Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Endocrine Peptides Test Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Endocrine Peptides Test Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Endocrine Peptides Test Market Size & Forecast, 2020-2028
4.5.1 Endocrine Peptides Test Market Size and Y-o-Y Growth
4.5.2 Endocrine Peptides Test Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Estradiol (E2)
5.2.2 Dehydroepiandrosterone Sulfate (DHEAS)
5.2.3 Human Chorionic Gonadotropin (hCG)
5.2.4 Progesterone
5.2.5 Luteinizing Hormone (LH)
5.2.6 Thyroid Stimulating Hormone (TSH)
5.2.7 Thyroid Prolactin
5.2.8 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Physicians’ offices
6.2.3 Commercial Laboratories
6.2.4 Health Care Centers
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Endocrine Peptides Test Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Endocrine Peptides Test Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Estradiol (E2)
9.6.2 Dehydroepiandrosterone Sulfate (DHEAS)
9.6.3 Human Chorionic Gonadotropin (hCG)
9.6.4 Progesterone
9.6.5 Luteinizing Hormone (LH)
9.6.6 Thyroid Stimulating Hormone (TSH)
9.6.7 Thyroid Prolactin
9.6.8 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Physicians’ offices
9.10.3 Commercial Laboratories
9.10.4 Health Care Centers
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Estradiol (E2)
10.6.2 Dehydroepiandrosterone Sulfate (DHEAS)
10.6.3 Human Chorionic Gonadotropin (hCG)
10.6.4 Progesterone
10.6.5 Luteinizing Hormone (LH)
10.6.6 Thyroid Stimulating Hormone (TSH)
10.6.7 Thyroid Prolactin
10.6.8 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Physicians’ offices
10.10.3 Commercial Laboratories
10.10.4 Health Care Centers
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Estradiol (E2)
11.6.2 Dehydroepiandrosterone Sulfate (DHEAS)
11.6.3 Human Chorionic Gonadotropin (hCG)
11.6.4 Progesterone
11.6.5 Luteinizing Hormone (LH)
11.6.6 Thyroid Stimulating Hormone (TSH)
11.6.7 Thyroid Prolactin
11.6.8 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Physicians’ offices
11.10.3 Commercial Laboratories
11.10.4 Health Care Centers
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Estradiol (E2)
12.6.2 Dehydroepiandrosterone Sulfate (DHEAS)
12.6.3 Human Chorionic Gonadotropin (hCG)
12.6.4 Progesterone
12.6.5 Luteinizing Hormone (LH)
12.6.6 Thyroid Stimulating Hormone (TSH)
12.6.7 Thyroid Prolactin
12.6.8 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Physicians’ offices
12.10.3 Commercial Laboratories
12.10.4 Health Care Centers
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Estradiol (E2)
13.6.2 Dehydroepiandrosterone Sulfate (DHEAS)
13.6.3 Human Chorionic Gonadotropin (hCG)
13.6.4 Progesterone
13.6.5 Luteinizing Hormone (LH)
13.6.6 Thyroid Stimulating Hormone (TSH)
13.6.7 Thyroid Prolactin
13.6.8 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Physicians’ offices
13.10.3 Commercial Laboratories
13.10.4 Health Care Centers
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Endocrine Peptides Test Market: Competitive Dashboard
14.2 Global Endocrine Peptides Test Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Quest Diagnostics
14.3.2 Siemens Healthcare
14.3.3 Abbott Laboratories
14.3.4 bioMerieux
